Modern antiplatelet agents in coronary artery disease.

Hdl Handle:
http://hdl.handle.net/10147/292584
Title:
Modern antiplatelet agents in coronary artery disease.
Authors:
Power, Rachel F; Hynes, Brian G; Moran, Darragh; Yagoub, Hatim; Kiernan, Gary; Ruggiero, Nicholas J; Kiernan, Thomas J
Affiliation:
Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland.
Citation:
Modern antiplatelet agents in coronary artery disease. 2012, 10 (10):1261-72 Expert Rev Cardiovasc Ther
Journal:
Expert review of cardiovascular therapy
Issue Date:
Oct-2012
URI:
http://hdl.handle.net/10147/292584
DOI:
10.1586/erc.12.127
PubMed ID:
23190065
Abstract:
Dual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.
Language:
en
MeSH:
Animals; Coronary Artery Disease; Drug Design; Drug Therapy, Combination; Humans; Individualized Medicine; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12
ISSN:
1744-8344

Full metadata record

DC FieldValue Language
dc.contributor.authorPower, Rachel Fen_GB
dc.contributor.authorHynes, Brian Gen_GB
dc.contributor.authorMoran, Darraghen_GB
dc.contributor.authorYagoub, Hatimen_GB
dc.contributor.authorKiernan, Garyen_GB
dc.contributor.authorRuggiero, Nicholas Jen_GB
dc.contributor.authorKiernan, Thomas Jen_GB
dc.date.accessioned2013-05-21T14:29:34Z-
dc.date.available2013-05-21T14:29:34Z-
dc.date.issued2012-10-
dc.identifier.citationModern antiplatelet agents in coronary artery disease. 2012, 10 (10):1261-72 Expert Rev Cardiovasc Theren_GB
dc.identifier.issn1744-8344-
dc.identifier.pmid23190065-
dc.identifier.doi10.1586/erc.12.127-
dc.identifier.urihttp://hdl.handle.net/10147/292584-
dc.description.abstractDual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Expert review of cardiovascular therapyen_GB
dc.subject.meshAnimals-
dc.subject.meshCoronary Artery Disease-
dc.subject.meshDrug Design-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshHumans-
dc.subject.meshIndividualized Medicine-
dc.subject.meshPlatelet Aggregation Inhibitors-
dc.subject.meshPurinergic P2Y Receptor Antagonists-
dc.subject.meshReceptor, PAR-1-
dc.subject.meshReceptors, Purinergic P2Y12-
dc.titleModern antiplatelet agents in coronary artery disease.en_GB
dc.contributor.departmentDepartment of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland.en_GB
dc.identifier.journalExpert review of cardiovascular therapyen_GB
dc.description.provinceMunsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.